Actuate Therapeutics, INC Form 4 insider transactions

Following Actuate Therapeutics' IPO, director Aaron G.L. Fletcher and related entities including Bios Equity Partners reported conversions of preferred stock and notes into common stock, along with warrant exercises and option grants.

Leslie W. Kreis, along with associated entities including BIOS Equity Partners, reported changes in beneficial ownership of Actuate Therapeutics, Inc. common stock.

Following Actuate Therapeutics' IPO, Bios Equity Partners and related entities converted preferred stock and convertible notes into common stock and exercised warrants, resulting in adjustments to their beneficial ownership.

Director Dan Zabrowski reports acquiring 15,000 stock options in Actuate Therapeutics following the company's initial public offering.

Daniel Schmitt, CEO of Actuate Therapeutics, reports the acquisition of 544,111 restricted stock units following the company's initial public offering.

Paul Lytle, CFO of Actuate Therapeutics, was granted 234,971 stock options following the company's initial public offering on August 14, 2024.

Director Jason A. Keyes acquired 30,000 non-qualified stock options in Actuate Therapeutics, Inc. following the company's initial public offering.

Amy L Ronneberg, a director of Actuate Therapeutics, acquired 30,000 non-qualified stock options on August 12, 2024, which vest over three years.

Director Roger Sawhney reports the acquisition of 30,000 non-qualified stock options in Actuate Therapeutics, Inc. following the company's IPO.